Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
Sell
40
BDUUF Quote, Financials, Valuation and Earnings
Last price:
$0.60
Seasonality move
:
2.12%
Day range:
$0.60 - $0.60
52-week range:
$0.60 - $0.77
Dividend yield:
3.68%
P/E ratio:
20.49x
P/S ratio:
3.05x
P/B ratio:
3.12x
Volume:
--
Avg. volume:
3
1-year change:
-22.07%
Market cap:
$9.6B
Revenue:
$3.1B
EPS (TTM):
$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDUUF
Bangkok Dusit Medical Services PCL
|
-- | -- | -- | -- | -- |
|
BUGDF
Bumrungrad Hospital PCL
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI
|
-- | -- | -- | -- | $8.00 |
|
IGC
IGC Pharma
|
$305K | -$0.02 | 3.39% | -50% | $3.88 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NIVF
NewGenIvf Group
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDUUF
Bangkok Dusit Medical Services PCL
|
$0.60 | -- | $9.6B | 20.49x | $0.01 | 3.68% | 3.05x |
|
BUGDF
Bumrungrad Hospital PCL
|
$7.91 | -- | $6.3B | 31.81x | $0.09 | 1.86% | 9.44x |
|
CVM
CEL-SCI
|
$2.51 | $8.00 | $7.6M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma
|
$0.34 | $3.88 | $26.8M | -- | $0.00 | 0% | 19.81x |
|
NBY
NovaBay Pharmaceuticals
|
$0.57 | $0.85 | $3.3M | -- | $0.00 | 0% | 0.16x |
|
NIVF
NewGenIvf Group
|
$2.64 | -- | $2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDUUF
Bangkok Dusit Medical Services PCL
|
7.11% | 0.305 | 2.25% | 1.12x |
|
BUGDF
Bumrungrad Hospital PCL
|
0.08% | 0.050 | 0.01% | 4.73x |
|
CVM
CEL-SCI
|
-- | 1.145 | -- | -- |
|
IGC
IGC Pharma
|
2.1% | -0.278 | 0.51% | 0.21x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.186 | 1.51% | 0.75x |
|
NIVF
NewGenIvf Group
|
-- | -0.738 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDUUF
Bangkok Dusit Medical Services PCL
|
$306.1M | $165.3M | 14.38% | 15.71% | 20.2% | $129.4M |
|
BUGDF
Bumrungrad Hospital PCL
|
$91.3M | $61.4M | 27.69% | 27.72% | 34.95% | $50.9M |
|
CVM
CEL-SCI
|
-- | -$6.4M | -- | -- | -- | -$4.4M |
|
IGC
IGC Pharma
|
$104K | -$1.9M | -114.2% | -116.24% | -730.74% | -$1.4M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NIVF
NewGenIvf Group
|
-- | -- | -- | -- | -- | -- |
Bangkok Dusit Medical Services PCL vs. Competitors
-
Which has Higher Returns BDUUF or BUGDF?
Bumrungrad Hospital PCL has a net margin of 15.48% compared to Bangkok Dusit Medical Services PCL's net margin of 28.23%. Bangkok Dusit Medical Services PCL's return on equity of 15.71% beat Bumrungrad Hospital PCL's return on equity of 27.72%.
Company Gross Margin Earnings Per Share Invested Capital BDUUFBangkok Dusit Medical Services PCL37.03% $0.01 $3.4B BUGDFBumrungrad Hospital PCL50.5% $0.06 $869.7M -
What do Analysts Say About BDUUF or BUGDF?
Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand Bumrungrad Hospital PCL has an analysts' consensus of -- which suggests that it could fall by --. Given that Bangkok Dusit Medical Services PCL has higher upside potential than Bumrungrad Hospital PCL, analysts believe Bangkok Dusit Medical Services PCL is more attractive than Bumrungrad Hospital PCL.
Company Buy Ratings Hold Ratings Sell Ratings BDUUFBangkok Dusit Medical Services PCL0 0 0 BUGDFBumrungrad Hospital PCL0 0 0 -
Is BDUUF or BUGDF More Risky?
Bangkok Dusit Medical Services PCL has a beta of 0.320, which suggesting that the stock is 67.998% less volatile than S&P 500. In comparison Bumrungrad Hospital PCL has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BDUUF or BUGDF?
Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.01 per share corresponding to a yield of 3.68%. Bumrungrad Hospital PCL offers a yield of 1.86% to investors and pays a quarterly dividend of $0.09 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. Bumrungrad Hospital PCL pays out 52.75% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDUUF or BUGDF?
Bangkok Dusit Medical Services PCL quarterly revenues are $826.7M, which are larger than Bumrungrad Hospital PCL quarterly revenues of $180.8M. Bangkok Dusit Medical Services PCL's net income of $127.9M is higher than Bumrungrad Hospital PCL's net income of $51M. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 20.49x while Bumrungrad Hospital PCL's PE ratio is 31.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 3.05x versus 9.44x for Bumrungrad Hospital PCL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDUUFBangkok Dusit Medical Services PCL3.05x 20.49x $826.7M $127.9M BUGDFBumrungrad Hospital PCL9.44x 31.81x $180.8M $51M
-
Which has Higher Returns BDUUF or CVM?
CEL-SCI has a net margin of 15.48% compared to Bangkok Dusit Medical Services PCL's net margin of --. Bangkok Dusit Medical Services PCL's return on equity of 15.71% beat CEL-SCI's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDUUFBangkok Dusit Medical Services PCL37.03% $0.01 $3.4B CVMCEL-SCI-- -$2.40 -- -
What do Analysts Say About BDUUF or CVM?
Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 9462.71%. Given that CEL-SCI has higher upside potential than Bangkok Dusit Medical Services PCL, analysts believe CEL-SCI is more attractive than Bangkok Dusit Medical Services PCL.
Company Buy Ratings Hold Ratings Sell Ratings BDUUFBangkok Dusit Medical Services PCL0 0 0 CVMCEL-SCI1 0 0 -
Is BDUUF or CVM More Risky?
Bangkok Dusit Medical Services PCL has a beta of 0.320, which suggesting that the stock is 67.998% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.196%.
-
Which is a Better Dividend Stock BDUUF or CVM?
Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.01 per share corresponding to a yield of 3.68%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDUUF or CVM?
Bangkok Dusit Medical Services PCL quarterly revenues are $826.7M, which are larger than CEL-SCI quarterly revenues of --. Bangkok Dusit Medical Services PCL's net income of $127.9M is higher than CEL-SCI's net income of -$6.6M. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 20.49x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 3.05x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDUUFBangkok Dusit Medical Services PCL3.05x 20.49x $826.7M $127.9M CVMCEL-SCI-- -- -- -$6.6M
-
Which has Higher Returns BDUUF or IGC?
IGC Pharma has a net margin of 15.48% compared to Bangkok Dusit Medical Services PCL's net margin of -711.67%. Bangkok Dusit Medical Services PCL's return on equity of 15.71% beat IGC Pharma's return on equity of -116.24%.
Company Gross Margin Earnings Per Share Invested Capital BDUUFBangkok Dusit Medical Services PCL37.03% $0.01 $3.4B IGCIGC Pharma40.47% -$0.02 $6.4M -
What do Analysts Say About BDUUF or IGC?
Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1050.19%. Given that IGC Pharma has higher upside potential than Bangkok Dusit Medical Services PCL, analysts believe IGC Pharma is more attractive than Bangkok Dusit Medical Services PCL.
Company Buy Ratings Hold Ratings Sell Ratings BDUUFBangkok Dusit Medical Services PCL0 0 0 IGCIGC Pharma2 0 0 -
Is BDUUF or IGC More Risky?
Bangkok Dusit Medical Services PCL has a beta of 0.320, which suggesting that the stock is 67.998% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.503, suggesting its more volatile than the S&P 500 by 50.252%.
-
Which is a Better Dividend Stock BDUUF or IGC?
Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.01 per share corresponding to a yield of 3.68%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDUUF or IGC?
Bangkok Dusit Medical Services PCL quarterly revenues are $826.7M, which are larger than IGC Pharma quarterly revenues of $257K. Bangkok Dusit Medical Services PCL's net income of $127.9M is higher than IGC Pharma's net income of -$1.8M. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 20.49x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 3.05x versus 19.81x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDUUFBangkok Dusit Medical Services PCL3.05x 20.49x $826.7M $127.9M IGCIGC Pharma19.81x -- $257K -$1.8M
-
Which has Higher Returns BDUUF or NBY?
NovaBay Pharmaceuticals has a net margin of 15.48% compared to Bangkok Dusit Medical Services PCL's net margin of -49.65%. Bangkok Dusit Medical Services PCL's return on equity of 15.71% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital BDUUFBangkok Dusit Medical Services PCL37.03% $0.01 $3.4B NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About BDUUF or NBY?
Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.2%. Given that NovaBay Pharmaceuticals has higher upside potential than Bangkok Dusit Medical Services PCL, analysts believe NovaBay Pharmaceuticals is more attractive than Bangkok Dusit Medical Services PCL.
Company Buy Ratings Hold Ratings Sell Ratings BDUUFBangkok Dusit Medical Services PCL0 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is BDUUF or NBY More Risky?
Bangkok Dusit Medical Services PCL has a beta of 0.320, which suggesting that the stock is 67.998% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.
-
Which is a Better Dividend Stock BDUUF or NBY?
Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.01 per share corresponding to a yield of 3.68%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDUUF or NBY?
Bangkok Dusit Medical Services PCL quarterly revenues are $826.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bangkok Dusit Medical Services PCL's net income of $127.9M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 20.49x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 3.05x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDUUFBangkok Dusit Medical Services PCL3.05x 20.49x $826.7M $127.9M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns BDUUF or NIVF?
NewGenIvf Group has a net margin of 15.48% compared to Bangkok Dusit Medical Services PCL's net margin of --. Bangkok Dusit Medical Services PCL's return on equity of 15.71% beat NewGenIvf Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDUUFBangkok Dusit Medical Services PCL37.03% $0.01 $3.4B NIVFNewGenIvf Group-- -- -- -
What do Analysts Say About BDUUF or NIVF?
Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand NewGenIvf Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Bangkok Dusit Medical Services PCL has higher upside potential than NewGenIvf Group, analysts believe Bangkok Dusit Medical Services PCL is more attractive than NewGenIvf Group.
Company Buy Ratings Hold Ratings Sell Ratings BDUUFBangkok Dusit Medical Services PCL0 0 0 NIVFNewGenIvf Group0 0 0 -
Is BDUUF or NIVF More Risky?
Bangkok Dusit Medical Services PCL has a beta of 0.320, which suggesting that the stock is 67.998% less volatile than S&P 500. In comparison NewGenIvf Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BDUUF or NIVF?
Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.01 per share corresponding to a yield of 3.68%. NewGenIvf Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. NewGenIvf Group pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDUUF or NIVF?
Bangkok Dusit Medical Services PCL quarterly revenues are $826.7M, which are larger than NewGenIvf Group quarterly revenues of --. Bangkok Dusit Medical Services PCL's net income of $127.9M is higher than NewGenIvf Group's net income of --. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 20.49x while NewGenIvf Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 3.05x versus -- for NewGenIvf Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDUUFBangkok Dusit Medical Services PCL3.05x 20.49x $826.7M $127.9M NIVFNewGenIvf Group-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…
Where Will Coinbase Stock Be in 5 Years?
If you’ve been anywhere near the crypto world over the…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
55
SBET alert for May 27
SharpLink Gaming [SBET] is up 454.46% over the past day.
Buy
57
RGC alert for May 27
Regencell Bioscience Holdings [RGC] is down 9.77% over the past day.
Buy
90
OKLO alert for May 27
Oklo [OKLO] is up 10.05% over the past day.
